Peer review process
Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors.
Read more about eLife’s peer review process.Editors
- Reviewing EditorMarcelo MoriState University of Campinas, Campinas, Brazil
- Senior EditorDavid JamesUniversity of Sydney, Sydney, Australia
Reviewer #1 (Public review):
Summary:
Zhang et al. describe a delicate relationship between Tet2 and FBP1 in the regulation of hepatic gluconeogenesis.
Strengths:
The studies are very mechanistic, indicating that this interaction occurs via demethylation of HNF4a. Phosphorylation of HNF4a at ser 313 induced by metformin also controls the interaction between Tet2 and FBP1.
Weaknesses:
The results are briefly described, and oftentimes, the necessary information is not provided to interpret the data. Similarly, the methods section is not well developed to inform the reader about how these experiments were performed. While the findings are interesting, the results section needs to be better developed to increase confidence in the interpretation of the results.
Reviewer #2 (Public review):
Summary:
This study reveals a novel role of TET2 in regulating gluconeogenesis. It shows that fasting and a high-fat diet increase TET2 expression in mice, and TET2 knockout reduces glucose production. The findings highlight that TET2 positively regulates FBP1, a key enzyme in gluconeogenesis, by interacting with HNF4α to demethylate the FBP1 promoter in response to glucagon. Additionally, metformin reduces FBP1 expression by preventing TET2-HNF4α interaction. This identifies an HNF4α-TET2-FBP1 axis as a potential target for T2D treatment.
Strengths:
The authors use several methods in vivo (PTT, GTT, and ITT in fasted and HFD mice; and KO mice) and in vitro (in HepG2 and primary hepatocytes) to support the existence of the HNF4alpha-TET-2-FBP-1 axis in the control of gluconeogenesis. These findings uncovered a previously unknown function of TET2 in gluconeogenesis.
Weaknesses:
Although the authors provide evidence of an HNF4α-TET2-FBP1 axis in the control of gluconeogenesis, which contributes to the therapeutic effect of metformin on T2D, its role in the pathogenesis of T2D is less clear. The mechanisms by which TET2 is up-regulated by glucagon should be more explored.